Sunday, July 26, 2026

BTC $64,394 ▲ 0.13%

LIVE

ADA$0.165+0.10%ETH$1,877+0.18%LINK$8.39+0.19%SOL$74.68+0.28%BTC$64,394+0.13%XRP$1.10+0.15%S&P 5007,412+0.05%Nasdaq24,976−0.64%Dow51,947+0.46%RUT2,930−0.35%TNX4.68%−0.51%TYX5.16%−0.17%FVX4.43%−0.78%IRX3.81%+0.13%VIX18.58−0.64%GOLD$4,070.80+0.51%SILVER$58.91+1.47%OIL$89.31−3.12%DXY101.47−0.00%NVDA$206.84−0.92%AAPL$333.02+3.53%TSLA$313.03−2.08%META$595.19−1.80%MSFT$381.70+0.03%AMZN$232.11−0.66%GOOGL$319.74+0.65%Fear & Greed26 — FearADA$0.165+0.10%ETH$1,877+0.18%LINK$8.39+0.19%SOL$74.68+0.28%BTC$64,394+0.13%XRP$1.10+0.15%S&P 5007,412+0.05%Nasdaq24,976−0.64%Dow51,947+0.46%RUT2,930−0.35%TNX4.68%−0.51%TYX5.16%−0.17%FVX4.43%−0.78%IRX3.81%+0.13%VIX18.58−0.64%GOLD$4,070.80+0.51%SILVER$58.91+1.47%OIL$89.31−3.12%DXY101.47−0.00%NVDA$206.84−0.92%AAPL$333.02+3.53%TSLA$313.03−2.08%META$595.19−1.80%MSFT$381.70+0.03%AMZN$232.11−0.66%GOOGL$319.74+0.65%Fear & Greed26 — Fear

Tag

retatrutide

1 article

U.S. Equities2d ago

Eli Lilly's Retatrutide FDA Bid Targets $25B Peak Sales in $100B Obesity Market

Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.